Search hospitals > Arkansas > Springdale
Highlands Oncology Group
Claim this profileSpringdale, Arkansas 72762
Global Leader in Non-Small Cell Lung Cancer
Global Leader in Breast Cancer
Conducts research for Tumors
Conducts research for Cancer
Conducts research for Lung Cancer
104 reported clinical trials
8 medical researchers
Summary
Highlands Oncology Group is a medical facility located in Springdale, Arkansas. This center is recognized for care of Non-Small Cell Lung Cancer, Breast Cancer, Tumors, Cancer, Lung Cancer and other specialties. Highlands Oncology Group is involved with conducting 104 clinical trials across 199 conditions. There are 8 research doctors associated with this hospital, such as J. Thaddeus Beck, Joseph T Beck, Eric S Schaefer, MD, and Joseph Thaddeus Beck.Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
KRAS positive
2Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
Top PIs
J. Thaddeus BeckHighlands Oncology Group11 years of reported clinical research
Studies Breast Cancer
Studies Melanoma
16 reported clinical trials
33 drugs studied
Joseph T BeckHighlands Oncology Group7 years of reported clinical research
Studies Breast Cancer
Studies Cancer
15 reported clinical trials
37 drugs studied
Eric S Schaefer, MDHighlands Oncology Group2 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
11 reported clinical trials
27 drugs studied
Joseph Thaddeus BeckHighlands Oncology Group2 years of reported clinical research
Studies Breast Cancer
Studies Tumors
6 reported clinical trials
22 drugs studied
Clinical Trials running at Highlands Oncology Group
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Colorectal Cancer
Tumors
Solid Tumors
Lung Cancer
Melanoma
Bladder Cancer
Small Cell Lung Cancer
PF-07220060 + Fulvestrant
for Advanced Breast Cancer
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: * are 18 years of age or older; * are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; * have advanced or metastatic breast cancer after taking other treatments before this study; * have not taken or need to take medications that are not allowed by the study protocol; * do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: * Fulvestrant alone taken as shot into the muscle. * Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: * imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. * the study doctor thinks the participant is no longer benefitting from the study medicine. * has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. * the participant chooses to stop taking part.
Recruiting2 awards Phase 3
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Imlunestrant
for Early Breast Cancer
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Highlands Oncology Group?
Highlands Oncology Group is a medical facility located in Springdale, Arkansas. This center is recognized for care of Non-Small Cell Lung Cancer, Breast Cancer, Tumors, Cancer, Lung Cancer and other specialties. Highlands Oncology Group is involved with conducting 104 clinical trials across 199 conditions. There are 8 research doctors associated with this hospital, such as J. Thaddeus Beck, Joseph T Beck, Eric S Schaefer, MD, and Joseph Thaddeus Beck.